Recent announcements

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
2023
September
Press Release
18 Sep
2023

POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands

Enables the efficient expansion of surface targets for radioisotope delivery

2023
August
Press Release
14 Aug
2023

POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023. Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first patient dosed expected in Q1 2024. Company released its first terbium-161 preclinical data, and announced additional isotope supply partnerships for actinium-225 and lead-212.

2023
July
Press Release
31 Jul
2023

ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177

The expanded agreement broadens the supply of ITM’s non-carrier-added lutetium-177 (n.c.a. 177Lu) to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT’s development pipeline.

2023
June
Press Release
26 Jun
2023

POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress

Auger electron and beta emitting isotope terbium-161 was paired with POINT’s FAP-targeted PNT6555 ligand and showed robust anti-tumor efficacy, similar to actinium-225 and lutetium-177 labeled PNT6555. Preclinical proof-of-concept established for synergistic interaction of immuno- and radioligand therapies with lutetium-177 labeled PNT6555.

2023
June
Press Release
26 Jun
2023

POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands

POINT’s vertically integrated platform together with AdvanCell’s lead-212 (212Pb) generator technology enables both the development and scaled commercialization of 212Pb-labeled radioligand therapies.

2023
June
Press Release
12 Jun
2023

POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors

Announced the filling of its vacant board seat with the appointment of Bridget Martell, M.A., M.D. to its Board of Directors.

2023
June
Press Release
7 Jun
2023

POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023

Register online today at https://hub.pointbiopharma.com/investor-day-june-2023

2023
May
Press Release
25 May
2023

POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO

PNT2004 program’s phase 1 FRONTIER trial design to be presented. Abstract to be released at 5:00 PM ET, May 25th. Poster to be available starting at 9:00 AM ET, June 3rd.